Ubs Group Ag Theseus Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.12 - $4.18 $24,312 - $47,936	11,468 Added 106.68%	22,218 $89,000
Q3 2023 Nov 09, 2023	BUY	$2.66 - $10.04 $17,343 - $65,460	6,520 Added 154.14%	10,750 $28,000
Q2 2023 Aug 11, 2023	SELL	$7.28 - $11.82 $19,080 - $30,980	-2,621 Reduced 38.26%	4,230 $39,000
Q1 2023 May 12, 2023	BUY	$5.21 - $14.05 $11,498 - $31,008	2,207 Added 47.52%	6,851 $60,000
Q4 2022 Feb 08, 2023	BUY	$4.69 - $8.36 $21,780 - $38,823	4,644 New	4,644 $23,000
Q2 2022 Aug 10, 2022	SELL	$5.04 - $14.05 $10,286 - $28,676	-2,041 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$8.75 - $14.51 $13,361 - $22,156	-1,527 Reduced 42.8%	2,041 $24,000
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $32,040 - $71,681	3,568 New	3,568 $45,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.